Announcements Trials
Browse Landscape

Phase

Phase 1 4

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 10Other solid neoplasm 7CNS 7Gastrointestinal 6Dermatologic 6Tumor-Agnostic 4Genitourinary 2Breast 2Head & Neck 1Endocrine 1

Conditions

Neoplasms 3Neoplasm Metastasis 1

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × AZD 6244 × Tumor-Agnostic × Clear all
NCT00463814 2026-05-29

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

AstraZeneca

Phase 1 Active not recruiting
58 enrolled
Tumor-Agnostic

Neoplasms

NCT03745989 2023-07-27

MK-8353-014

Merck Sharp & Dohme LLC

Phase 1 Completed
30 enrolled 19 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT02322749 2016-08-31

A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male Volunteers

AstraZeneca

Phase 1 Completed
48 enrolled 16 charts
Tumor-Agnostic

Neoplasms

NCT02238782 2016-04-05

A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.

AstraZeneca

Phase 1 Completed
21 enrolled 4 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡